Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | HMGCR | P04035 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23344929 | 0.89 | HSP90AA1 (0.48) | HSD17B10KDM4EALDH1A1TSHRGAA | |
| SCHEMBL29739588 | 0.85 | KDM4E (0.46) | HSD17B10KDM4EALDH1A1TSHRMAPT | |
| SCHEMBL22549255 | 0.84 | HSD17B10 (0.41) | HSD17B10KDM4EHRH4GAAMAPT | |
| SCHEMBL14595541 | 0.82 | HSD17B10 (0.48) | HSD17B10KDM4EALDH1A1HRH4 | |
| SCHEMBL18007575 | 0.78 | HSD17B10 (0.72) | HSD17B10KDM4EHRH4GAAMAPT | |
| SCHEMBL37832 | 0.74 | ALDH1A1 (0.40) | HSD17B10KDM4EALDH1A1TSHRHRH4 | |
| SCHEMBL305093 | 0.74 | GABRA1 (0.43) | HSD17B10KDM4EALDH1A1TSHRHRH4 | |
| SCHEMBL23113220 | 0.74 | CHRNA7 (0.35) | KDM4E | |
| Bromide SCHEMBL10759230 | 0.72 | HSD17B10 (0.39) | HSD17B10KDM4EALDH1A1TSHRHRH4 | |
| SCHEMBL22543799 | 0.72 | HSD17B10 (0.39) | HSD17B10KDM4EHRH4HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7081454-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | WITTMAN MARK D | 2006-04-13 | — | — | US | disclosed |
| EP-1545543-A2 | NOVEL TYROSINE KINASES INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004031401-A2 | NOVEL TYROSINE KINASES INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | ABL1, YES1, FER | HSD17B10 1265/4885KDM4E 1067/4885ALDH1A1 1038/4885 |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | ABL1, FER, ERBB2 | HSD17B10 1366/4885KDM4E 991/4885ALDH1A1 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.